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Abstract 
A novel neurological syndrome, mitochondrially inherited sensory ataxic 
neuropathy (SAN), was discovered in Golden Retriever dogs in Sweden.  The 
purpose of the work described in the present thesis was to investigate the 
phenotype, clinical course and genotype of this syndrome by clinical, neurological 
and pathological examination of affected dogs, as well as to determine the mode of 
inheritance and identify the causative mutation. 
Mitochondrially inherited SAN in Golden Retriever dogs has an insidious onset 
during puppyhood. Affected dogs develop ataxia and dysmetria, with abnormal 
postural reactions and depressed spinal reflexes.  
The disease has a chronic, slowly progressive clinical course. Of the affected dogs 
investigated within the scope of this thesis, none became non-ambulatory or died 
spontaneously during the study period. However, about half of the affected dogs 
were euthanized because of neurological impairment before attaining 4 years of age.  
Post mortem examinations of affected dogs revealed degenerative changes in both 
the central and the peripheral nervous system. A chronic active central–peripheral 
axonopathy, neuroaxonal dystrophy-like alterations in spinal cord and brainstem, 
and a neuron-sparing encephalopathy with spongiosis in the basal nuclei were the 
most prominent findings.  
A maternal mode of inheritance was concluded from pedigree analysis, indicating 
a causative mutation in the mitochondrial DNA. Laboratory data confirmed that 
affected dogs had malfunctioning mitochondria. A single base-pair deletion in the 
mitochondrial tRNA
Tyr gene was found and proven to be pathogenic.  
In summary, canine SAN is a slowly progressive neurodegenerative disease with 
onset in puppyhood. The disease is maternally inherited and is caused by a mutation 
in the mitochondrial tRNA
Tyr gene. 
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  10 1  Introduction  
 
Several neurodegenerative diseases with a familial distribution have been 
described in dogs (Sisó et al.,  2006). Typically, such diseases are breed-
related with onset of clinical signs in young dogs and clinical features that 
reflect the nature and distribution of degenerating cells in the nervous system 
that is unique for each disease. Commonly, rather few cases of each disease 
have been reported. Even though many diseases are suspected to be 
inherited, the underlying genetic defects are largely unknown. 
A novel canine neurological disease in Golden Retriever dogs was 
proven to be maternally inherited and so far has been seen only in that 
breed. For the first time it has been described clinically as well as post 
mortem. With the features of a mitochondrially inherited syndrome it has 
implications for health and breeding practice in this breed, and may also 
serve as a spontaneous model for comparative studies.  
1.1  Background  
Almost a decade ago a number of Golden Retriever dogs with strikingly 
similar gait abnormalities were examined by practising veterinarians without 
attaining either an aetiological or pathological-anatomical diagnosis. The 
abnormal gait of the affected dogs was described as quite characteristic and 
with onset during puppyhood. The affected dogs were related to each other 
on the maternal side. The first clinical case examined by a board-certified 
neurologist (the author) was admitted to the University Clinic, Swedish 
University of Agricultural Sciences (SLU), Uppsala, Sweden in 2002. The 
clinical picture of that dog was not in agreement with any other previously 
described canine disease. Since then, an increasing number of new cases 
have been admitted for examination. With more dogs examined, the clinical 
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this disease was inherited maternally was reinforced over time. Studies were 
initiated of the mitochondrial molecular genetics in the affected families of 
dogs, and this assumption was later confirmed.  
The effects of mutations in mitochondrial deoxyribonucleic acid (DNA) 
differ in many aspects from those passed on by Mendelian inheritance. A 
short review of the basic facts of mitochondrial genetics and mitochondrial 
diseases is therefore presented as an introduction. 
1.2  The mitochondrial genome 
Mitochondria are cellular organelles, which originated by endosymbiosis of 
primitive bacteria during the evolution of the eukaryotic cell (Gray, 1993). 
In the mitochondria, electron transfer and oxidative phosphorylation take 
place in the respiratory chain, resulting in the production of adenosine-5'-
triphosphate (ATP). Mitochondria harbour their own DNA. The sequence 
of human mitochondrial DNA (mtDNA) was first published in 1981 
(Anderson  et al.,  1981) (Cambridge Reference Sequence), and the first 
mtDNA mutations causing human diseases were described in 1988 (Holt et 
al., 1988; Wallace et al., 1988). The complete nucleotide sequence of canine 
mtDNA was published in 1998 (Kim et al., 1998). Mammalian mtDNA is a 
circular double-stranded molecule, which contains 37 genes and 
approximately 16 500 base-pairs. The 37 genes encode 13 protein subunits 
of the respiratory chain enzymes together with 22 transfer ribonucleic acids 
(tRNAs) and two ribosomal RNAs. All the other subunits of the respiratory 
chain enzymes, and also the factors involved in replication, transcription and 
translation of mtDNA, are encoded from the nuclear genome and imported 
into the mitochondria.  
1.3  Mutations in the mitochondrial DNA 
Every cell contains hundreds to thousands of mtDNA molecules. The 
mtDNA replicates irrespective of the cell cycle and replication occurs also in 
post-mitotic cells. The mutation rate in mtDNA is higher than in nuclear 
DNA, because of a less effective repair mechanism (Kang & Hamasaki, 
2006). Single nucleotide polymorphisms of mtDNA are therefore relatively 
common, and they are important clues utilized both in phylogenetic 
research and in forensic medicine. Occasionally, a mutation results in 
pathogenic effects. Disease-causing mutations in the mtDNA can occur 
spontaneously in somatic cells and give rise to non-hereditary acquired 
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pathogenesis of the neurodegenerative diseases Alzheimer’s disease and 
Parkinson’s disease (Lin & Beal, 2006), as well as being a cause of ageing 
(Harman, 1956; Harman, 1992) and occurring in neoplastic tissue (Polyak et 
al.,  1998). The mtDNA is transferred maternally from generation to 
generation. Disease-causing mtDNA mutations can also appear in germ-line 
cells and thus be inherited.  
Mutations of different types occur in the mitochondrial genome. There 
are, for example, point mutations (a single base-pair substitution), large scale 
deletions (a loss of a part of the DNA molecule, containing sometimes many 
thousand base-pairs), and single base-pair deletions associated with clinical 
disease (http://www.mitomap.org/). 
1.4  Heteroplasmy, the threshold effect and the genetic 
bottleneck 
Concerning the role of mtDNA in mitochondrial dysfunction and clinical 
disease, some important concepts are the phenomena of heteroplasmy, the 
threshold effect and the genetic bottleneck (Hauswirth & Laipis, 1982; Ashley et 
al.,  1989; Chinnery et al.,  1997;  Moslemi  et al.,  1998). Because of the 
polyploid nature of the mtDNA content in any one cell, both mutant and 
wild type mtDNA can coexist in the cell, a condition called heteroplasmy. 
The proportion of mutant mtDNA to total mtDNA is called the mutant 
load. With just one type of mtDNA present – wild type or mutant – the 
condition is called homoplasmy. A cell maintains its normal activity of 
oxidative phosporylation unless a pathogenic mutant mtDNA reaches a 
certain level, called the threshold effect of heteroplasmy. The number of 
mitochondria, and hence mtDNA molecules, is decreased dramatically in 
precursors to primary oocytes (Jansen, 2000), which undergo cell division 
without mtDNA replication at that stage. By random segregation in 
primordial germ cells, this phenomenon increases the likelihood of 
differences in the level of heteroplasmy in mature oocytes from the same 
heteroplasmic female (Jenuth et al., 1996). Thus, it is possible that a clinically 
unaffected heteroplasmic mother gives birth to offspring that are severely, 
mildly or not at all clinically affected. This phenomenon is called the 
mitochondrial genetic bottleneck.  
  13 1.5  Pathogenicity of mutations in the mitochondrial DNA 
Because of the relatively large amount of single nucleotide polymorphisms 
in the mitochondrial genome, a number of criteria should be met before a 
mutation is determined to be pathogenic. Whenever a disease is associated 
with a mutation in the mitochondrial genome it is appropriate to consider a) 
the presence of heteroplasmy for the mutation, b) the correlation between 
the degree of heteroplasmy and the clinical phenotype, c) histochemical and 
biochemical evidence of mitochondrial dysfunction in tissue biopsies, and d) 
the evolutionary conservation of the mutated site in the mtDNA molecule. 
A pathogenic mutation in a tRNA gene is correlated with reduced steady-
state levels of the mutated tRNA. In addition, a strong indicator that a 
mutation is pathogenic is evidence for malfunctioning mtDNA in cybrid 
cells (cell lines depleted of their own mtDNA fused with mitochondria from 
a patient). (DiMauro & Schon, 2001; McFarland et al., 2004a; DiMauro & 
Davidzon, 2005).  
1.6  Mutations in different types of mitochondrial genes 
Mitochondrial dysfunction can develop from mtDNA mutations in tRNA 
genes, ribosomal RNA genes or in protein coding genes. The biochemical 
expression differs between these mutations. For example, whereas 
pathogenic mutations in tRNA genes influence the majority of complexes in 
the respiratory chain, mutations in protein coding genes affect primarily 
single complexes in the chain.  
1.7  Diseases from mitochondrial mutations 
More than 500 mtDNA mutations and rearrangements associated with 
diseases in humans have been reported (http://www.mitomap.org/). 
Mitochondrial disorders comprise a very heterogeneous group of 
phenotypes. In general, the clinical signs reflect most often a dysfunction of 
post-mitotic tissues that consume high levels of energy, such as the nervous 
system and striated muscles. The presenting symptoms include seizures, 
ataxia, ophthalmoplegia, ptosis, blindness, deafness, muscle weakness and 
cardiomyopathy, as isolated symptoms or in different syndromic 
combinations that more or less overlap. The clinical pictures of many 
diseases associated with mtDNA mutations include also a diversity of other 
signs, e.g. diabetes mellitus, sideroblastic anaemia, intestinal pseudo-
obstruction, ovarian failure and short stature in humans (DiMauro & 
Davidzon,  2005;  Taylor & Turnbull, 2005). Mitochondrial diseases are 
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considered a major burden for society (Schaefer et al., 2004). 
Several disease phenotypes in humans have been correlated with specific 
mtDNA mutations, but the relationship between genotype and phenotype 
for mitochondrial disorders is only partly understood and confusion exists 
regarding the correlation between disease presentation and genetic 
background for many cases. One factor partly explaining this relationship is 
that different levels of heteroplasmy may occur in different parts of the 
human body (Sciacco et al., 1994; Moslemi et al., 1998; Tanji et al., 2000; 
Kärppä et al., 2005). Other important contributing factors that determine the 
phenotype for some mtDNA-related diseases are the nuclear genetic 
background (Dunbar et al., 1995; Cock et al., 1998; McFarland et al., 2004b; 
Hudson et al, 2005a), interactions with other mitochondrial genes (Fischel-
Ghodsian, 1998; Hudson et al., 2007), and environmental factors (Prezant et 
al., 1993; Estivill et al., 1998; Kirkman et al., 2009). 
Mitochondrial dysfunction can also evolve from nuclear DNA mutations. 
Nuclear DNA encodes many enzymes in the respiratory chain, several 
factors needed in other biochemical processes in the mitochondria and also 
factors involved in the replication, transcription, translation and maintenance 
of mtDNA as well as fission and fusion of the mitochondria. As an example, 
pathogenic mutations in either of the nuclear genes POLG,  C10Orf2 or 
ANT1 result in incorrect replication of mtDNA. Secondary to these nuclear 
DNA mutations, development of pathogenic mutations in the mtDNA may 
occur because of errors induced by the defective replication process. Human 
mitochondrial diseases have been correlated with mutations in these nuclear 
genes (Agostino 2003; Van Goethem et al., 2003; Van Goethem et al., 2004; 
Hudson et al., 2005b; Gago et al., 2006; Milone et al., 2008). 
In animals, only one spontaneous mitochondrially inherited disease has 
previously been fully revealed genetically: i.e. canine spongiform 
leucoencephalomyelopathy in Australian Cattle dogs and Shetland 
Sheepdogs (Li et al.,  2006). The underlying genetic defect was a point 
mutation in the protein-encoding mt-cytochrome b gene, which encodes a 
subunit of the respiratory chain complex III. The associated clinical picture 
was whole body tremor and inability to ambulate in young puppies, with a 
progressive clinical course. 
1.8  Diagnostics in mitochondrial diseases 
In a patient with neurological or neuromuscular clinical signs, the clinical 
features, family history and/or pathomorphological characteristics may 
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case, a muscle biopsy for biochemical and microscopic analyses may give 
valuable information and should be considered before molecular genetic 
studies are performed.  
Preferably, muscle biopsies should be harvested from a muscle rich in 
oxidative type I fibres and hence rich in mitochondria. In dogs, a high 
percentage of type I fibres has been found in antigravity muscles (Armstrong 
et al., 1982). Some of the stains useful for histochemistry are the Gomori’s 
trichrome stain, succinate dehydrogenase (SDH) stain and cytochrome 
oxidase (COX) stain. Gomori’s trichrome highlights mitochondria, giving a 
picture called “ragged red fibres” when mitochondria have accumulated to a 
certain point, which is not specific for but may be seen with some human 
mitochondrial disorders (Bourgeois & Tarnopolsky, 2004). The SDH and 
COX stain, respectively, reflect the activity of complex II and complex IV 
of the respiratory chain (Bourgeois & Tarnopolsky, 2004). Complex II is the 
only complex entirely encoded by the nuclear DNA whereas complex IV 
contains subunits encoded by the mtDNA. With a combined SDH/COX-
stain, fibres coloured blue have SDH activity but lacks COX activity, which 
is indicative of a mitochondrial disorder. Common findings in muscle 
biopsies from humans with mtDNA mutations are COX-negative fibres and 
ragged red fibres (Bourgeois & Tarnopolsky, 2004). Confirmation of such 
findings in dogs is considered difficult owing to the larger mitochondrial 
volume in canine muscles compared with those of humans (Wakshlag et al., 
2004). Previous reports of COX-negative fibres (Paciello et al., 2003; Tauro 
et al., 2008) and ragged red fibres (Vijayasarathy et al., 1994; Olby et al., 
1997; Paciello et al., 2003) in dogs are rare and only concern single dogs. 
Electron microscopically, findings of paracrystalline inclusions in 
mitochondria are characteristic for human adult mitochondrial muscle 
pathology (Bourgeois & Tarnopolsky, 2004). Moreover, a biochemical 
diagnosis of a mitochondrial disorder may be established by measurements of 
the ATP production rate and activity of respiratory chain complexes in 
muscle mitochondria (Wibom et al., 2002). 
 
 
 
 
  16 2  Aims of the thesis  
The overall aim of the present thesis was to investigate a novel neurological 
syndrome which presented clinically as sensory ataxic neuropathy in the 
Golden Retriever breed, thereby also establishing an animal model for a 
spontaneous mitochondrially inherited disease. 
 
The specific aims were: 
 
¾ To describe and define clinical and post mortem features to serve as 
inclusion criteria 
 
¾ To evaluate the clinical course and survival 
 
¾ To determine the mode of inheritance, to identify the causative 
mutation in the mitochondrial genome of affected dogs if maternally 
inherited, and to provide advice on how to reduce its incidence 
 
¾ To relate the neurological signs to neuropathological changes and 
molecular mechanisms 
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  18 3  Materials and methods 
The materials and methods used in this study are summarized below. For 
further details, see papers I–IV. 
3.1  Animals 
3.1.1  Affected dogs  
A total of 27 privately owned Golden Retriever dogs diagnosed with 
mitochondrially inherited sensory ataxic neuropathy (SAN) serve as case 
material in this thesis. Of these, 15 were females and 12 males, and at 
presentation the median age was 16 months (range 6–77 months). The 
diagnosis was based on the clinical features but was studied further according 
to the methods below. Twenty of the dogs were examined by the author at 
the SLU in Uppsala, Sweden, while the remaining seven were included by 
scrutinizing records from other veterinarians (Table 1, Figure 1).  
3.1.2  Maternally related dogs 
Thirty-three Golden Retriever dogs (28 females and five males) maternally 
related to the affected dogs were included in the studies (papers II and IV). 
Samples from all these dogs were used in molecular genetic analyses. Eleven 
of these dogs, at a median age of 60 months (range 7–131 months), were 
examined in a clinical setting similar to that of the affected dogs (Table 1, 
Figure 1).  
3.1.3  Controls 
A total of 78 Golden Retriever dogs, 48 females and 30 males, served as 
controls in different parts of the studies (papers I, II and IV). These dogs 
were maternally unrelated to affected dogs as far as their pedigrees and 
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(http://www.skk.se/). Samples from all these dogs were used in the 
molecular genetic analyses. Thirteen of those Golden Retriever dogs were 
admitted to SLU for clinical signs of gait disorder but did not fulfil the 
clinical diagnostic criteria for SAN. The remainder were clinically healthy 
dogs with regard to neurological gait disorders. Healthy control dogs used 
for reference purposes in electrophysiology studies (n=11, papers I and IV) 
were age-matched to the affected dogs. The control dogs used for 
biochemical and microscopic analyses of muscle tissue (n=5, paper II) were 
pair-wise age-matched to the affected dogs. In addition, samples from 86 
dogs of 18 other breeds and 6 wolves (see paper II) were used in the 
molecular genetic analyses (Table 1). 
Table 1. The number of Golden Retriever dogs used for each procedure in this thesis. 
 Affected  Maternally 
related 
Controls 
Evaluation because of gait disorder  27  0  13 
Neurological exam 1’  27  11  34 
Neurological exam 2’  10  1  1 
Neurological exam 3’  3  0  0 
Electrophysiology 1’  18  4  12 
Electrophysiology 2’  6  1  0 
Molecular genetics  22  33  78 
Post mortem  9  1  0 
Muscle biopsy  5  0  5 
Video tape  15  0  0 
Total  27  33  78 
 
The local Animal Ethics Committee in Uppsala (no. C110/4, C161/5 and 
C138/6) and the Swedish Animal Welfare Agency (no. 31-1437/04 and 
2006-0561) approved the experimental designs. The owners of privately 
owned dogs all provided written consent to participation in the study. All 
the 27 affected dogs belonged to 27 different owners. Some owners of 
control dogs and/or maternally related dogs owned more than one included 
dog each. 
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Y
Z
Male and female, not further evaluated
Male and female, affected
Neurologically examined
Mutant load in blood analysed
Neurologically examined and mutant load in blood analysed
 
Figure  1. A schematic pedigree of Golden Retriever dogs affected by mitochondrially 
inherited sensory ataxic neuropathy (SAN) and their relatives. Only maternal lineages with 
affected or neurologically examined dogs or dogs analysed for mutant load are depicted. 
Entire litters are included only for affected dogs. Arrow points at index case. 
  21 3.2  Clinical procedures 
3.2.1  Clinical history 
For all affected dogs, information about the presenting clinical signs, age at 
onset and progression of signs were retrieved from owners and/or breeders 
and/or referring veterinarians. Also, if the dog had died, the age at and 
reason for death were documented.  
3.2.2  Clinical and neurological examination 
The primary investigator performed a full clinical and neurological 
examination of 20 affected dogs, 11 maternally related Golden Retriever 
dogs, 13 maternally unrelated Golden Retriever dogs with gait disorders, 
and 21 maternally unrelated healthy Golden Retriever controls (papers I, II 
and IV) (Table 1). In the neurological examination, assessment of 
consciousness, behaviour, posture, gait, cranial nerve functions, postural 
reactions, spinal reflexes and pain perception were included. Parts of the 
neurological examination of 15 affected Golden Retriever dogs were video 
taped to allow simultaneous comparisons between patients (Table 1). Five of 
those 15 affected dogs were also video taped at a later neurological 
examination, to allow simultaneous comparisons between occasions. The 
neurological examination was repeated ≥6 months (range 6–51 months) after 
the primary examination in 10 affected dogs (Figure 1 in paper IV) (Table 
1). The neurological status of these 10 dogs was scored in such a way that a 
comparison between neurological examinations at different occasions was 
possible (see paper IV). In the affected cases not examined in person by the 
author (n=7), the results from clinical and neurological examinations were 
provided by clinical records from other veterinarians. In addition, serum 
chemistry, blood lactate analysis, serum antinuclear antibodies, serology for 
Borrelia burgdorferi sensu lato, Anaplasma phagocytophilum and Neospora 
caninum, polymerase chain reaction (PCR) for Anaplasma phagocytophilum 
DNA, radiology and cerebrospinal fluid (CSF) analysis were performed in 
some dogs (Tables 2 and 3). Some of these examinations had already been 
performed by the referring veterinarians prior to admittance to SLU.  
 
 
 
 
 
  22 Table 2. An overview of serum chemistry examinations in dogs affected by mitochondrially inherited 
sensory ataxic neuropathy and in 1
st and 2
nd degree relatives.  
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S-alanine aminotransferase  11  14 n.  a.  1  1  0 
S-albumin  8  9  4  0  0 - 
S-alkaline phosphatase  10  13 n.  a.  1  0 - 
S-amylase  7  7 n.  a. 0  0 - 
S-aspartate aminotransferase  19  27 n.  a.  3  9  0 
S-bile acids  11  13 n.  a.  0  0 - 
S-blood urea nitrogen  10  12  0  1  1  0 
S-calcium  10  11  0  1  0 - 
S-cobalamin  1  1  0  0  0 - 
S-creatine kinase  19  27 n.  a.  3  9  0 
S-creatinine  11  14  0  1  0 - 
S-chloride  7  7  0  0  1  0 
S-copper  7  7  1  0  0 - 
S-folic acid  1  1  0  0  0 - 
S-fructosamine  13  16  1  1  9  0 
S-globulins  9  9  0  0  0 - 
S-glucose  5  6  0  2  1  0 
S-iron  1  1  0  0  0 - 
S-lipase  7  7 n.  a. 0  0 - 
S-magnesium  7  7  0  1  0 - 
S-phosphorus  7  7  1  3  0 - 
S-potassium  11  12  0  0  1  0 
S-protein electrophoresis  8  8  1  1  0 - 
S-sodium  10  11  0  2  1  0 
S-total protein  8  9  0  0  0 - 
S-troponin  14  15 n.  a.  3  9  1, above 
S-thyroid stimulating hormone  17  21 n.  a.  0  0 - 
S-thyroxine (free and total)  17  21  0  0  0 - 
S-zinc  8  8  0  3  0 - 
n. a. = not applicable 
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sensory ataxic neuropathy. 
Examination  Number of affected 
dogs examined 
Number of results 
outside of reference 
range 
Venous blood lactate  8  0 
Antinuclear antibodies in serum  7  0 
Serology Neospora caninum  9  0 
Serology Anaplasma phagocytophilum  12  2 
Serology Borrelia burgdorferi sensu lato  12  2 
PCR Anaplasma phagocytophilum  5  0 
Myelography  3  0 
Plain spinal radiographs  9  0 
CSF cytology, cell count, protein  4  0 
CSF = cerebrospinal fluid 
3.2.3  Electrophysiology 
Electrophysiological examinations were undertaken in 18 affected dogs (8 
months to 6 years old), four maternally related dogs (2–10 years old), one 
maternally unrelated control dog with a non-SAN gait disorder, and 11 
healthy control dogs (5 months to 8 years old) using the neurophysiology 
equipment Counterpoint MK2 (Medtronic A/S, Skovlunde, Denmark). Six 
affected dogs were re-examined electrophysiologically ≥2 years later (when 
3–8 years old) (papers I and IV) (Table 1). Dogs were sedated with a 
combination of medetomidine (Domitor vet, 1 mg/ml, 0.01 ml/kg, Orion, 
Sollentuna, Sweden) and butorphanol (Torbugesic, 10 mg/ml, 0.01 ml/kg, 
ScanVet, Animal Health A/S, Fredensborg, Denmark) intramuscularly pre- 
examination. Electromyography (EMG) of proximal and distal muscles of 
the thoracic and pelvic limbs was conducted using concentric needle 
electrodes (Myoline 40 mm, Judex, Aalborg, Denmark). Motor nerve 
conduction studies (MNCS) of ulnar, peroneal and tibial nerves were 
performed using surface electrodes (Medelec Gold Disc Electrodes part. no. 
54426T, Cephalon, Norresundby, Denmark), while disposable sensory 
needle electrodes (15mm*0.70mm (22G), Medtronic A/S, Skovlunde, 
Denmark) were used for sensory nerve conduction studies (SNCS) of 
superficial radial, ulnar, peroneal and tibial nerves. The same examiner 
(DVM Eva Örvind) performed all the electrophysiological examinations. 
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A total of nine affected dogs and one mother of two affected dogs were 
necropsied (Tables 1 and 4). Samples from the nervous system and muscle 
tissue were either frozen or fixed in formalin or glutaraldehyde. Formalin- 
and glutaraldehyde-fixed samples from the necropsied dogs were studied by 
the same examiner, Dr. Kaspar Matiasek. For paper I, post mortems of four 
affected dogs aged 11–30 months at euthanasia were performed (dogs 1 to 4, 
Table 4). In paper II, degrees of heteroplasmy were determined from frozen 
samples of different body tissues from three of the necropsied dogs (dogs 3, 5 
and 7, Table 4). For paper III, in-depth post mortem examinations of five 
affected dogs aged 4–10 years at euthanasia were conducted (dogs 5 to 9, 
Table 4). The post mortem of a mother of two SAN-dogs (dog 10, Table 4) 
was studied in paper IV.  
Table 4. An overview of age and gender of the necropsied dogs by paper in studies of mitochondrially 
inherited sensory ataxic neuropathy in the Golden Retriever breed. 
Dog  Age  Gender  Paper I  Paper II  Paper III  Paper IV 
1  11  months  male  X     
2  15  months  female  X     
3  23 months  female  X  X     
4  30  months  female  X     
5  4  years  male   X  X  
6  4  years  male     X  
7  5  years  male   X  X  
8  5  years  female     X  
9  9  years  female     X  
10  10  years  female      X 
Frozen muscle biopsies were processed and stained using haematoxylin and 
eosin (HE), Gomori’s trichrome, periodic acid Schiff (PAS), PAS/diastase, 
oil red O, acid phosphatase, alkaline phosphatase, SDH, COX and ATPase 
techniques. Formalin-fixed material was also processed using HE, PAS, 
PAS/diastase and Masson’s trichrome stained sections, as well as Luxol fast 
blue, cresyl echt violet, Woelcke-Spielmeyer-Schröder, Bodian, glial 
fibrillary acidic protein (GFAP) and neurofilament (NF) staining  for the 
central nervous system. Nerve biopsies were processed according to standard 
protocols: in short, all samples underwent immersion in 2.5% glutaraldehyde 
followed by osmium tetroxide (OsO4) postfixation, repeated buffer rinses 
and a graded alcohol series before being embedded in epoxy resin. For 
routine histological inspection, semithin sections (0.5 µm) were mounted on 
triethoxysilane-coated glass slides and stained with azur II–methylene blue–
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teasing. Thereby, 300 single nerve fibres with at least five internodes were 
considered representative.  
3.4  Pedigree analyses 
The pedigrees of affected dogs and their families were retrieved from the 
dog registry of the Swedish Kennel Club (http://www.skk.se/). Inbreeding 
coefficients for five-generation pedigrees of affected dogs and for all age-
matched Golden Retriever dogs in the same registry were calculated using 
the software package Pedig (Boichard, 2002). Both common ancestors and 
matrilineal relatives born in 2001–2005 were searched for in this registry. 
Information about the total number of Golden Retriever litters born in 
Sweden during the years 2001–2005 was retrieved from the stud book. The 
maternal transmission of SAN was evaluated statistically by comparing the 
prevalence of affected dogs in two groups of offspring. First, we retrieved 
information about the identity of all dogs in litters (n=12) where the mother 
of one of our affected dogs was one of the litter mates. Then we divided all 
dogs (n=97) in those litters into one group of males (n=39) and one group 
of females (n=58). The next step was to count the number of affected 
offspring relative to the total number of offspring from the male group and 
the female group, respectively.  
3.5  Molecular genetics  
The complete mtDNA was re-sequenced in four affected dogs, one 
unaffected maternally related dog and two unrelated control Golden 
Retriever dogs. The mutant load in samples from 22 affected Golden 
Retriever dogs, 33 maternal relatives and all control Golden Retriever dogs 
(n=78) was estimated by a quantitative oligonucleotide ligation assay 
(qOLA) method. A northern blot analysis was applied to measure the steady-
state levels of three mitochondrially encoded tRNAs (the tRNA for tyrosine 
(Tyr), the tRNA for glutamine (Gln) and the tRNA for cysteine (Cys)) in 
muscle tissue from three affected dogs and two unrelated, unaffected control 
dogs (one Golden Retriever and one Dachshund). All the laboratory work 
in molecular genetics was performed by the same examiner, PhD student 
Izabella Baranowska. For further details about the analytical methods used, 
see paper II. 
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Fresh muscle biopsies were harvested from musculus quadriceps vastus medialis 
of five affected dogs (1–6 years of age) and five age-matched control Golden 
Retriever dogs (Table 1). Prior to surgery, the dogs were sedated with a 
combination of medetomidine (Domitor vet, 1 mg/ml, 0.01 ml/kg, Orion, 
Sollentuna, Sweden) and butorphanol (Torbugesic, 10 mg/ml, 0.01 ml/kg, 
ScanVet, Animal Health A/S, Fredensborg, Denmark), both administered 
intramuscularly. The skin and subcutaneous tissues at the incision site were 
anaesthetized locally with xylocaine (Xylocain 5 mg/ml, AstraZeneca, 
Södertälje, Sweden).  
Mitochondria were prepared from the excised muscle tissue according to 
the method of Wibom et al. (2002). Respiratory chain enzyme activities and 
rates of mitochondrial ATP production (Wibom et al.,  2002) were 
determined pair-wise (one case and one control) in a blinded fashion. In 
addition, citrate synthase activity was determined in muscle tissue and in 
isolated mitochondria (Wibom et al., 2002). 
Freshly frozen muscle biopsies from the same animals were used for 
histochemistry. Sections were stained with HE and Gomori’s trichrome and 
for oxidative enzymes (reduced nicotinamide adenine dinucleotide 
(NADH)-tetrazolidium reductase, SDH, COX and the combined reaction 
for SDH and COX). Pairs of biopsies (one case and one control) were 
stained on the same occasion and evaluated blindly. Muscle samples were 
also fixed in 2.5% glutaraldehyde for electron microscopy. For further details 
about the analytical methods used, see paper II. 
The presence of heteroplasmy in muscle homogenate and single muscle 
fibres was studied by restriction fragment length polymorphism, RFLP, in 
one case and one control dog (hitherto unpublished) as described previously 
(Moslemi et al., 1998). DNA from muscle homogenates of each dog and 10 
muscle fibres with reduced COX activity and five fibres with apparently 
normal COX activity (COX-positive) from the affected dog were subjected 
to PCR using a 6-carboxyfluorescein (6-FAM)-labelled forward primer 
(L5191-5210) and a reverse primer (H5383-5359). The amplified DNA-
fragments were digested with restriction enzyme BccI, which cleaves the 
mutant DNA, and the proportion of mutated DNA was calculated by 
GenScan software (Applied Biosystems, CA). The resolution of this method 
allows detection of wild type levels of about ≥ 2%.   
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The survival of affected dogs from birth to euthanasia was demonstrated 
with a Kaplan–Meier diagram, using the procedure LIFETEST in SAS (SAS 
Institute Inc., Cary, NC, 27513, US). Electrophysiologic parameters from 
different groups of dogs were compared using the two-sample t-test, and 
comparisons between different occasions of examination of the same dogs 
were compared by the paired t-test (Minitab 12.23, Minitab Inc.). Statistical 
significance was set to p < .05. 
The maternal transmission of SAN was tested by applying Fischer’s exact 
test to the prevalence calculated in different groups of offspring (see 3.4). 
Hybridization intensity for the different tRNAs of affected dogs in the 
northern blot analysis was compared with that of control dogs using the 
Student’s t-test. Differences in the rate of ATP production and enzyme 
activities between the group of affected dogs and the group of control dogs 
were tested for significance by the two-sample t-test. 
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The results from these studies are summarized below. For further details, see 
papers I–IV. 
4.1  Onset of gait disturbances in puppies 
The clinical signs in the affected dogs (n=27) were reported to have been 
noticed first at 2–8 months of age (n=26), and in one case the age at onset 
was reported as “less than one year”. It was reported that the first impression 
of any abnormalities was often rejected by the owners based on the 
assumption that the dogs were “just being clumsy and puppyish”.  
The first signs observed by the owners were in most cases referred to as 
unstable or uncoordinated pelvic limbs (n=9) or a strange gait in the pelvic 
limbs (n=8). However, one owner had instead first noticed a weakness in 
the carpi. In another case, difficulties in getting up from a sitting position 
were reported as the presenting sign. All the other owners (n=8) made 
remarks about a generalized gait disturbance as the presenting sign.  
With time, all affected dogs developed further clinical signs that were 
noticed by the owners. The signs also became more severe. Besides the 
obvious gait disturbances, a majority of the owners reported that the dogs 
were reluctant to walk on slippery floors and on stairs, had difficulties in 
entering cars and that the pelvic limb claws were worn. In addition, a 
majority (5/8) of the adult (≥1-year-old) male dogs were reported to 
maintain a body posture like that of a bitch at urination. More uncommon 
signs included in the clinical history reported by the owners were 
development of urinary incontinence in adolescence (n=3), inability to 
swim (n=3), wagging of the hind part at urination/defecation (n=2), 
nibbling the skin of pelvic limbs without exhibiting dermatological changes 
(n=2), not being ticklish in the pelvic limb paws (n=2), showing signs of 
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(n=1), intolerance of hot weather (n=2), rarely coming into heat (n=2), 
cow-hocks (n=1) and strabismus on excitement (n=1).  
4.2  Neurological deficits 
The general physical examination of affected dogs did not identify any 
clinically relevant findings except signs associated with neurological 
dysfunction, nor did serum chemistry, blood lactate analysis, serology or 
screening for infectious diseases with PCR, diagnostic imaging or 
cerebrospinal fluid analysis (Tables 2 and 3). Occasional values were found 
below or above the reference ranges: in all instances these were close to the 
reference values, and thus not paid further attention.  
At neurological examination, the gaits of all affected dogs were ataxic and 
conspicuously dysmetric (Figure 2). Especially in the pelvic limbs, the 
movements altered intermittently between hypermetria and hypometria. An 
inability to bear weight on the pelvic limbs with knees extended was seen – 
but not at every step. Truncal swaying was apparent in a few cases (n=3). 
Postural reactions and spinal reflexes were decreased in all affected dogs. The 
most prominent finding was absent (n=20) or obviously decreased (n=7) 
patellar reflexes. The pelvic limbs were more affected by neurological 
deficits than the thoracic limbs. The most obvious abnormality in the 
thoracic limbs was hyperextension of the carpi, which was present in a 
majority of the dogs examined in person by the author (13/20). Among the 
dogs examined neurologically by other veterinarians (n=7), for only two 
dogs was the thoracic limb posture mentioned, and then as hyperextended 
carpi. The only cranial nerve deficit observed was a bilaterally decreased 
menace reaction in two cases. Pain perception was within normal limits in 
all dogs. No dog seemed to be in pain. The neuroanatomical diagnosis in 
SAN-dogs referred to the sensory compartment of the spinal reflex arcs in 
both pelvic and thoracic limbs, and to afferent proprioceptive pathways in 
sensory nerves and spinal cord. 
The constellation of signs was similar from dog to dog but the severity of 
signs differed between dogs, apparently irrespective of age or duration from 
onset of signs. Two cases examined at 8 months of age were already severely 
ataxic whereas one case examined at 8 years of age was only mildly ataxic.  
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Figure 2. Serial images showing the gait of a severely ataxic Golden Retriever dog affected by 
mitochondrially inherited sensory ataxic neuropathy.  
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4.3  Slowly progressive clinical course  
Dogs that were re-examined neurologically had more severe deficits at re-
examination (paper IV). This was also in accordance with the impressions of 
owners/breeders and information from referring veterinarians. The 
neurological signs reported waxed and waned to some degree, and in 
general this did not seem correlated with any factors observed by the 
owners. However, there were two exceptions; one dog was said to 
deteriorate every winter and one dog was worse repeatedly when 
abnormally thin. Some owners also reported that their dogs improved 
during adolescence in handling stairs, slippery floors or entering cars. 
However, no dog was ever free of signs after onset, and over time all the 
dogs deteriorated. 
Eighteen affected dogs were deceased prior to the last follow up (June 
2009). All of them had been euthanized. Sixteen dogs had been euthanized 
because of neurological impairment and two dogs (9 and 10 years old) were 
euthanized owing to unrelated incapacitating diseases. About half of all the 
affected dogs included were euthanized before 4 years of age, and yet some 
dogs (n=3) were euthanized at an older age, owing to neurological 
impairment (Figure 3 in paper IV). Nine dogs were still alive; six of them 
were more than 6 years old at the time of last follow up (June 2009). So far, 
no dog has become non-ambulatory as a result of SAN.  
4.4  Related dogs that were affected subclinically  
The  11 maternally related dogs that were examined neurologically were 
considered to be unaffected by gait disturbances by their owners, with two 
exceptions: one dog had had surgery for a ruptured cruciate ligament several 
years before and one had been diagnosed with hip dysplasia. None of the 
dogs showed ataxia at examination, but three of these dogs (all three were 
mothers, of two, three and five affected dogs respectively) had other 
neurological deficits in agreement with deficits seen in dogs affected by 
SAN. For example, all of them had decreased or absent patellar reflexes. 
These three neurologically affected related dogs were considered to be 
subclinical cases of SAN.  
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Dogs affected by SAN had significantly lower sensory nerve conduction 
velocities (SNCVs) than control dogs in all sensory nerves tested. The 
SNCVs were not dramatically low, and despite statistical significance, there 
was an overlap of individual values between the groups. Also, affected dogs 
with severe ataxia had lower mean SNCVs than affected dogs with mild 
ataxia in all four sensory nerves tested, but this was not statistically significant 
for any nerve. Concerning amplitudes in sensory nerve testing, MNCS and 
EMG, no conclusive differences from control dogs were found. One mother 
of three SAN-dogs had neurological deficits on neurological examination 
and the lowest SNCVs of all the dogs examined, but the MNCS were in 
accordance with published reference ranges (van Nes, 1986) and no 
abnormal discharge was found on EMG examination.  
4.6  Degenerative changes throughout the nervous system  
In the first four affected dogs (11–30 months old) that underwent necropsy, 
the neuropathological findings consisted of degeneration and loss of large 
myelinated Ia/b-afferents extending into the dorsal nerve roots and 
associated spinal white matter tracts. Further degenerative changes were seen 
in the ventral horns and descending motor pathways of the spinal cord. One 
of these dogs displayed presynaptic buttons and axonal spheroids throughout 
the ventral column of the spinal cord intumescences, identical to those seen 
with neuroaxonal dystrophy (NAD). The same dog had some eosinophilic 
spheroids close to nerve cell perikarya in the cerebellar roof nuclei, 
otherwise no conspicuous brain abnormalities were found at that time in any 
dog. Taken together, the changes in the central nervous system (CNS) and 
peripheral nervous system (PNS) were consistent with a chronic progressive 
central and peripheral sensorimotor axonopathy affecting in particular the 
proprioceptive pathways with very mild involvement of peripheral motor 
axons.  
In the five other affected dogs (4–9 years old) that were examined post 
mortem, more profound and widespread neurodegenerative changes were 
found. A typical symmetrical spatial distribution of different types of 
neurodegenerative changes was seen, consisting of spongiosis in the basal 
nuclei, most prominent in the caudate nuclei, with relative sparing of 
neurons and NAD-type alterations in spinal cord and brainstem nuclei in 
addition to the central–peripheral axonopathy.  
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progressive neurodegenerative changes of certain cell populations, especially 
in the extrapyramidal motor system in the brain and the general 
proprioceptive system. Two distinct patterns of pathology had developed: 
neuron-sparing encephalopathy in the basal nuclei and NAD-type 
alterations. The neurodegenerative alterations were more prominent in older 
dogs than in younger ones. 
A  10-year-old mother of two affected dogs was also necropsied. Post 
mortem examination revealed neurodegenerative changes in both CNS and 
PNS at histopathology. The findings consisted of a chronic, marked, 
predominantly axonal polyradiculoneuropathy and advanced stage 
neurodegeneration of vestibular and cuneate nuclei in the brainstem. 
4.7  Non–neurological manifestations in necropsied dogs  
Non-neurological manifestations at necropsy were found in four dogs. A 4-
year-old affected dog had enteritis, one 5-year-old affected dog had 
hypoplastic ovaries, and a 9-year-old affected dog had a metastasizing cardiac 
haemangiosarcoma and a mammary complex adenoma. One 10-year-old 
mother of two affected dogs had a mammary carcinoma with lung 
metastases. Another affected dog, 10 years old, was euthanized because of a 
tumour in the spleen, but this dog was not necropsied.  
4.8  Mitochondrial inheritance 
A common ancestor born in 1976 (female X) was in the maternal lineages of 
all affected dogs, for at most eight generations back in time (Figure 1). Her 
grandmother (female Z), born in 1971, was the oldest dog with descendants 
still alive potentially carrying the same mitochondrial mutation, which it was 
possible to find through the Swedish Kennel Club registry. During 2001–
2005, a total of 2180 Golden Retriever litters were registered in the stud 
book. Female Z had offspring through maternal lineages in 94 litters 
registered in the Swedish Kennel Club database during the same period, 
which constituted 4.3% of the registered litters in the breed. Dogs in the 
same mitochondrial lineage are also registered in Norway, Denmark, 
Finland and Estonia, and anecdotally exist in other countries e.g. Russia, 
France and the Netherlands.  
In those groups of offspring for which the prevalence of SAN was 
calculated, in the female group there were 25 affected offspring out of a total 
of 272 born. No affected dog had been diagnosed among 177 offspring in 
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was proven to be mitochondrial (p < .000001). The inbreeding coefficient 
for affected dogs born in 1997–2004 was very similar to the coefficient for 
the entire Golden Retriever population registered by the Swedish Kennel 
Club born during the same period (1.6% compared to 1.5%).  
4.9  Deletion in mtDNA 
A single base-pair deletion was identified in the mtDNA from affected dogs 
and maternal relatives. A “T” was deleted at position 5304 (∆T5304) in the 
mitochondrial genome, in the tRNA
Tyr gene. The disease was 
unambiguously associated with this sequence variant. This site in the 
mitochondrial genome is conserved in evolution and the deletion has never 
been reported in any other mammal. The mutation resulted in a deleted base 
in the TΨC stem of the tRNA
Tyr molecule.  
4.10 High mutant load 
All the affected dogs and all their tested clinically unaffected 1
st, 2
nd, 3
rd and 
4
th degree maternal relatives had a very low level of the wild type sequence 
in blood, ranging from 0 to 11.2%. Concerning the degree of heteroplasmy, 
the group of affected dogs was not possible to distinguish from these close 
maternal relatives. One entire litter with two affected dogs and six, 
according to the owners, unaffected dogs and their unaffected mother was 
included in the analyses. No differences in mutant load could be detected 
between affected and unaffected dogs in that family (unpublished data). All 
control dogs and wolves had 100% wild type sequence. Also two dogs traced 
back to female X, in a lineage spanning six generations from her in which 
no affected dogs were known hitherto, had 100% wild type sequence 
(unpublished data). In even more distant relatives (tracing back to female Z 
but not to female X) the degree of heteroplasmy varied from 5 to 60% wild 
type among dogs. These results indicated that female Z or some ancestor to 
her was the founder (Figure 1). 
The mutant load in body tissues (frontal lobe, spinal cord with dorsal root 
ganglia (7
th thoracic and 5
th lumbar), optic nerve, recurrent laryngeal nerve, 
pancreas, thyroid gland, and skeletal muscle of pelvic and thoracic limbs) was 
estimated in three affected dogs. All analysed tissues had a higher mutant 
load, close to 0% wild type, compared with the degree of heteroplasmy in 
blood cells from the same dogs. In RFLP analysis of COX-positive single 
muscle fibres and fibres with reduced COX activity of one affected case, no 
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the same molecular genetic method, the muscle homogenate from the 
control dog showed 100% wild type sequence whereas the homogenate 
from the affected dog had no detectable wild type sequence (unpublished 
data).  
4.11 Reduced steady-state levels of tRNA
Tyr 
By northern blotting, all three affected dogs showed significantly reduced 
steady-state levels of tRNA
Tyr compared with the two control dogs. 
Concerning the other mitochondrial tRNA species assessed, tRNA
Cys and 
tRNA
Gln, no differences were found in hybridization intensities between 
affected dogs and controls. These data indicated an increased degradation 
and hence an impaired stability of mutated tRNA
Tyr.  
4.12 Dysfunction of the respiratory chain 
In muscle biopsies from four out of the five affected dogs that were sampled, 
the ATP production rate and the enzyme activities in the respiratory chain 
complexes were reduced in a mode that indicated dysfunction of the 
respiratory chain units encoded by mtDNA. Moreover, the reduced 
activities of multiple enzymes with subunits encoded by mtDNA were in 
accordance with mutations in tRNA genes. One affected dog (dog 3, paper 
II) was not possible to distinguish from the controls with these assays.  
4.13 Bluish staining of muscle biopsies 
On combined staining for SDH/COX activity, four of the five sampled 
affected dogs had a bluish staining of the muscle fibres compared with their 
matched controls. This indicated a shift towards a lower COX activity 
compared with the SDH activity in the muscles of affected dogs. However, 
no fibres that showed a total lack of COX activity were detected and no 
ragged red fibres were found. One affected dog (dog 3, paper II) did not 
display any muscle pathology on histochemistry, in agreement with the non-
pathological biochemistry for the same dog. 
4.14 Inclusions in mitochondria 
On electron microscopy, one affected dog (dog 3, paper II) had 
paracrystalline inclusions in the mitochondria. This was the dog that was 
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No other dog had any clear signs of structural mitochondrial pathology.  
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5.1  The novelty of this neurological syndrome 
The clinical picture and pathomorphological changes of Golden Retriever 
dogs affected by the neurodegenerative disease SAN are unique. Breed-
related neurodegenerative diseases in dogs with clinical signs reflecting 
dysfunction of predominantly sensory parts of the nervous system, thus 
sharing some similarities with SAN, have been described. In some diseases, 
nociceptive loss is included as a clinical sign, e.g. for Border Collies and 
long-haired Dachshunds with sensory neuropathy (Duncan & Griffiths, 
1982; Wheeler, 1987; Vermeersch et al., 2005): this is a sign not detected in 
Golden Retriever dogs with SAN. In others, e.g. neuroaxonal dystrophy in 
Rottweiler dogs and Papillon dogs (Cork et al., 1983; Chrisman et al., 1984; 
Franklin et al., 1995), vestibulocerebellar signs are part of the clinical picture, 
in contrast to SAN.  
In addition, diseases that are partially similar to SAN in 
pathomorphological features have been described. In Rottweiler dogs and 
Papillon dogs (Cork et al., 1983; Chrisman et al., 1984; Franklin et al., 1995), 
breed-related neuroaxonal dystrophies have been described without 
concomitant basal nuclei degeneration or peripheral nerve pathology, a 
picture not similar to that of SAN in Golden Retriever dogs. Bilaterally 
symmetric degeneration of extrapyramidal nuclei has been reported in an 
English Springer Spaniel (Brenner et al., 1997), Kuvasz dogs (Hazlett et al., 
2005), Alaskan Husky dogs (Brenner et al., 2000), Yorkshire Terriers (Baiker 
et al., 2009) and Kerry Blue Terriers (de Lahunta & Averill, 1976). Only the 
Kuvasz dogs and Kerry Blue Terriers had involvement of the caudate nuclei 
and in no case were concomitant NAD-changes or peripheral nerve 
affection reported, distinguishing these diseases from canine SAN. In 
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observed central–peripheral axonopathy with axonal spheroids and 
presynaptic buttons in the CNS have similarities to SAN: however, the 
degenerative changes in the optic pathways but absence of degeneration of 
basal nuclei noted in Boxer dogs discern these two diseases from each other 
(Griffiths et al., 1980; Griffiths et al., 1985). A central–peripheral axonopathy 
in New Zealand Huntaway dogs has also been described, but no 
involvement of the basal nuclei or NAD-like changes were reported for 
these dogs (Jolly et al., 2000).  
Familial neurological diseases with onset in puppyhood have occurred 
previously in the Golden Retriever breed (Braund et al., 1989; Matz et al., 
1990; da Costa et al., 2009), but these are unlike canine SAN regarding both 
clinical and pathological features. Braund et al. (1989) and Matz et al. (1990) 
described a hypomyelinating polyneuropathy with onset in puppies of 6–7 
weeks old. These dogs had markedly diminished motor nerve conduction 
velocities suggesting involvement of peripheral motor nerve fibres to a larger 
extent than in SAN-dogs. da Costa et al. (2009) presented a multisystem 
axonopathy and neuronopathy with onset in puppies of 6–15 weeks old. 
The predominating signs were tetraparesis and severe muscle atrophy but 
not ataxia, in contrast to the features of SAN.  
There are some other reports of encephalopathies in dogs that have been 
proposed (Gruber et al., 2002) or proven (Li et al., 2006; Wood & Patterson, 
2001) to be mitochondrial disorders, of which neither the clinical picture 
nor the pathomorphological features resemble those of canine SAN. Also, it 
seems that in comparison with neurodegenerative diseases in humans or 
other mammals, no counterpart has been described. 
To summarize, in all these reports the combination of age at onset, 
clinical course, clinical and neurological signs, and the nature and 
distribution of neuropathological changes are not in agreement with the 
features of SAN; thus SAN in Golden Retriever dogs is considered to be a 
novel neurological syndrome. 
5.2  Characterization as a sensory ataxic neuropathy  
The disease in Golden Retriever dogs reported here was characterized as a 
sensory ataxic neuropathy owing to the neurological signs, in agreement 
with a similar clinical syndrome in humans. Sensory ataxic neuropathies 
present with loss of proprioceptive sensations and tendon reflexes, with 
preservation of muscle strength (Illa et al., 2001). This syndrome is associated 
with a number of aetiologies (Illa et al., 2001) and mitochondrial disorders 
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Okun & Bhatti, 2004; Van Goethem et al., 2004; Hudson et al., 2005b; 
Gago et al., 2006; Milone et al., 2008).  
5.3  Description and definition of criteria for clinical features 
A tentative diagnosis of SAN in Golden Retriever dogs can be made on 
clinical grounds, the basis being a combination of signalment, age at onset, 
history, clinical signs, neurological signs and clinical course. The diagnosis 
should be anticipated in a Golden Retriever dog of either gender, affected 
by ataxia as a pup with a progressive clinical course and with absent or 
decreased patellar reflexes besides unaffected general appearance. There are 
often affected dogs that are not-too-distant maternal relatives, but such 
information is often unavailable to owners.  
Besides the ataxia, all affected dogs have had hyporeflexia (7/27 dogs) or 
bilateral absence (20/27 dogs) of patellar reflexes as a consistent finding at 
neurological examination. This feature is considered very typical for SAN, 
even in the early stages. The three youngest cases at examination, 6 and 7 
months old, all had bilaterally absent patellar reflexes. The patellar reflex is 
the most reliable tendon reflex in the dog and should always be checked in 
neurological examination of dogs (de Lahunta & Glass, 2009a). Patellar reflex 
responses have been studied previously in normal dogs and abnormalities are 
not frequent; two of 72 dogs of <10 years old and four out of 14 dogs of 
≥10 years old had absent reflexes (Levine et al., 2002). To define the patellar 
reflexes as “lost”, as in paper I, is probably not accurate if it is not known 
whether the reflexes were present previously. They should be considered 
rather as just “absent” if they are not possible to elicit. 
The remainder of the clinical and neurological examination should be in 
agreement with the results described in section 4.2 and papers I and IV. To 
check for possible differential diagnoses, blood work, serological tests, 
diagnostic imaging, CSF analysis and electrophysiology may be indicated. At 
electrophysiology, the SNCV in peripheral nerves may be below reference 
ranges in cases of SAN, whereas MNCS and EMG are within reference 
ranges. These results are compatible with neuropathic diseases in humans 
that involve the peripheral portion of the sensory nerves (Tankisi et al., 
2005). Lactic acidaemia is present in many human patients with 
mitochondrial disorders (Tatuch et al., 1992; Fadic et al., 1997; Pulkes et al., 
2000; Sahashi et al., 2001; Liolitsa et al., 2003; Van Goethem et al., 2003; 
Kirby et al., 2004; Kärppä et al., 2005). Lactate measurements in SAN-dogs 
at rest were inconspicuous.  
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where neurological signs are first observed in older dogs cannot be excluded. 
However, in the case material studied here there is no suggestion for a late-
onset form of SAN.  
A genetic test for the causative deletion is now available commercially 
(http://www.hgen.slu.se/), and should test positive in an affected dog. It 
should also be noted that a positive genetic test means “carrier” and not 
automatically “affected”. This genetic test does not separate carriers from 
clinically affected dogs.  
5.4  Description and definition of criteria for post mortem 
features 
In young affected dogs, at 1–2 years of age, neuropathological changes 
consist predominantly of mild central–peripheral axonopathy. In the spinal 
cord, axonopathy is most pronounced in the fasciculus gracilis and the dorsal 
part of the lateral funiculus, followed by the fasciculus cuneatus and the 
ventral descending motor pathways. In peripheral nerves, ongoing Wallerian 
degeneration, particularly of large myelinated fibres, is seen, some fascicles 
being affected more severely than others. Histopathology of muscle tissue 
display subtle variation in fibre size, type II angular fibres and small group 
atrophy.  
In older dogs, axonal spheroids and presynaptic buttons in the ventral 
columns of the spinal cord, most prominent in the intumescences, are added 
to the histopathological appearance. The same kind of change is also seen in 
some brainstem nuclei (reticular nuclei, cuneate and accessory cuneate 
nuclei, nuclei of the spinal tract of cranial nerve V and olivary nuclei) and in 
association with the grey matter of the ponto- and spinocerebellum. In older 
dogs with a fully developed pathomorphological picture, degenerative 
changes of the extrapyramidal system are also seen, including a neuron-
sparing encephalopathy in the basal nuclei with spongiosis, which is most 
prominent in the caudate nuclei.  
In younger dogs, histological lesions can be overlooked easily unless the 
specific regions outlined above are carefully examined. The lesions can also 
be difficult to differentiate from post mortem changes if necropsy is delayed.  
So far, very young affected puppies have not been examined post mortem, 
but in these cases the lesions are expected to be even milder and more 
difficult to detect.  
Neoplastic diseases were diagnosed in three dogs, but were considered to 
be unrelated to the neurological syndrome. Even though there are 
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neoplasia (Polyak et al., 1998), no such conclusions were drawn in these 
cases because neoplastic diseases are common in the ageing Swedish dog 
population (Egenvall et al., 2000) and all three dogs with neoplasia were old.  
An association between the hypogonadism diagnosed post mortem in one 
affected dog and the mitochondrial disorder is not excluded, because a 
similar association has been seen in humans (Taylor & Turnbull, 2005). 
5.5  Clinical course and therapy 
The clinical course of SAN is chronic and slowly progressive. This statement 
is underlined by information from owners, breeders, referring veterinarians 
and repeated neurological examinations. The assessment of the degree of 
neurological deficit is subjective. Because of this, a single examiner 
performed all the primary and subsequent neurological examinations in the 
re-examined dogs, and in addition an effort to reduce biases by use of a 
scoring system and review of video tapes was introduced in paper IV.  
The disease onset is insidious, with the first signs in puppyhood. To date, 
it is not known whether affected dogs have any clinical signs already from 
birth. Their gait disorder is easily confused with “puppyish movements” at 
the beginning. An impression was obtained that owners who were used to 
observing the gait of normal puppies detected the gait disturbances earliest.  
No dog has become non-ambulatory during the disease course. At the 
last check-up, three dogs of 9–10 years old were still ambulatory. However, 
the main clinical problem in all dogs is limited activity associated with the 
abnormal gait. The most severe cases completely refused to walk on floors 
indoors and some owners had carpets all over their house to facilitate for 
their dog. 
The clinical course observed is considered to be the natural course of 
SAN. Non-steroidal anti-inflammatory drugs (NSAIDs) and/or 
corticosteroids had been used for short or longer periods in some dogs, but 
no clinical response was reported. Some dogs (n=3) were exercised 
assiduously by their owners and apparently overcame the reluctance to walk 
e.g. on stairs and on slippery floors over time. However, their neurological 
status deteriorated over time. 
No therapeutic trials have so far been initiated, owing to a lack of 
knowledge about the natural course of SAN and natural variations in this 
course. To evaluate treatment regimens, such knowledge is fundamental. 
The clinical management of humans affected by primary mtDNA disorders 
is mainly symptomatic, including for example anticonvulsant therapy for 
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specific agents against lactic acidosis. Supportive therapy with antioxidants, 
respiratory chain co-factors, carnitine, creatine, hormones or a high-fat diet 
aimed at improving the function of the respiratory chain are used 
commonly, and anecdotally some patients respond, though not all. A few 
controlled trials have resulted in contradictory results (Chinnery et al., 2006). 
Improvement as a result of physical training has been documented in 
patients with myopathy (Taivassalo et al., 1998) but the baseline capacity 
returned after the training period was over (Taivassalo et al., 2006).  
5.6  Survival 
Survival analysis suggests a guarded prognosis for dogs affected by SAN with 
respect to the expected canine lifespan, bearing in mind that “a full-length 
dog life” is a somewhat hypothetical concept in Sweden where most dogs 
are euthanized sooner or later. However, about half part of all affected dogs 
had been euthanized before 4 years-old. In a study of mortality in over 
350,000 insured Swedish dogs, the probability of death by 5 years for 
Golden Retriever dogs was 7% (Egenvall et al., 2005). The natural course 
until spontaneous death is not known in any SAN case studied, because all 
the contributing deceased dogs were euthanized. The time point for 
euthanasia was at the owners’ request. The time point elected for euthanasia 
due to neurological impairment is not always correlated with the relative 
severity of neurological signs but instead is thought to represent the 
respective owner’s tolerance of the gait disturbances of their dog. Degrees of 
ataxia in dogs examined by the author (n=20) are presented in Table 5.  
Table 5. Number of euthanized dogs and dogs still alive at last follow-up (June-09) with different 
degrees of ataxia at the last or the only neurological examination. Included are also the ages of the 
different dogs at these neurological examinations. All these dogs (n=20) were diagnosed with 
mitochondrially inherited sensory ataxic neuropathy and were examined neurologically by the author.  
 Mild  Mild– 
moderate 
Moderate Moderate– 
severe 
Severe 
Euthanized dogs  n = 2  
1 y, 8 y  
n = 3  
1 y, 2 y, 4 y 
n = 1  
8 m 
n = 2  
1 y, 3 y  
n = 4  
8 m, 10 m, 5 y, 5 y 
Dogs still alive  n = 1  
5 y 
n = 1  
5 y 
n = 3  
5 y, 6 y, 9 y 
n = 1  
3 y 
n = 2   
1 y, 3 y 
m = months old, y = years old 
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A hereditary pattern for this disease was indicated at an early stage because 
the affected dogs were related to each other and cases were clustered in 
some litters. A common ancestor in the maternal lineage of all the affected 
dogs was found, and maternal inheritance was eventually proven. Further 
analyses of the Swedish Kennel Club registry traced this maternal lineage 
back for 10 generations (Figure 1). This registry is detailed and contains 
reliable pedigree data, computerized from 1976. There are mandatory rules 
for the identification by tattoo or microchip for dogs registered in the 
database since 1997. Knowing the mode of inheritance, it is possible to 
reduce the incidence of this disease simply by not mating females from this 
matrilineal family. 
The basis for this thesis comprises investigations of 27 diagnosed clinical 
cases, of which 20 were examined by the author and seven dogs were 
examined neurologically by other veterinarians. All these dogs had both the 
clinical course and the pattern of neurological deficits in common, and were 
therefore included as affected dogs. In addition, some undiagnosed siblings 
and other maternal relatives with similar gait disturbances (n=8), according 
to breeders familiar with the diagnosed dogs, are depicted as affected dogs in 
Figure  1. Anecdotally, there are and have been additional cases in the 
Swedish Golden Retriever population. This is anticipated and does not 
challenge the conclusions about SAN. Also anecdotally, the first clinical case 
in Sweden suspected in retrospect to have had this disease was born in the 
late 1980s.  
The described pedigree of SAN-dogs is large compared with the 
pedigrees reported for almost all other maternally inherited diseases, the vast 
majority of them being human diseases. Extensive pedigrees of somewhat 
comparable sizes have been described for maternally inherited sensorineural 
deafness in a six-generation Israeli-Arab kindred (Jaber et al., 1992) and for 
Leber’s hereditary optic neuropathy in seven generations of Brazilians 
(Sadun et al., 2002) and an Australian six-generation pedigree (Sudoyo et al., 
1992). 
For dogs, only one other maternally inherited disease has been reported 
previously: canine spongiform leucoencephalomyelopathy in Australian 
Cattle dogs and Shetland Sheepdogs (Li et al., 2006). For both these breeds, 
the published pedigrees consisted of one healthy female dog and their 
affected offspring in three different litters each. The mutation was the same 
in both breeds (a point mutation in the cytochrome b gene), and they had 
the same nucleotide sequence in the D-loop of the mtDNA molecule, 
  45 indicating that these two families, through maternal lineages, may have 
originated from the same ancestor before the breeds were separated. 
5.8  Identification of the causative mutation  
A deletion was found at base-pair 5304 in the tRNA
Tyr g e n e  i n  t h e  
mitochondrial genome of affected dogs. This finding is in itself not sufficient 
to claim the mutation pathogenic. McFarland et al. (2004a) applied scoring 
criteria to mutations in mitochondrial tRNA genes, thereby categorizing the 
mutations as (i) definitely pathogenic; (ii) probably pathogenic; (iii) possibly 
pathogenic; (iv) neutral variants. This scoring system assesses 1) the 
evolutionary conservation of the base, 2) the number of independent reports 
about the association between disease and mutation, 3) the presence of 
heteroplasmy,  4) histochemical evidence of mitochondrial disease, 5) 
biochemical defects in complex I, III or IV, 6) segregation of the mutation 
with disease, 7) single-fibre studies, demonstrating higher levels of mutation 
in COX-negative muscle fibres, 8) steady-state levels of mutated 
mitochondrial tRNA, and 9) evidence of pathogenicity from cybrid cells. In 
this system, the SAN mutation falls into the category “definitely pathogenic” 
because the deletion is in an evolutionarily highly conserved site, 
heteroplasmy is present, there is weak histochemical evidence of 
mitochondrial disease, there are biochemical defects in complexes I, III and 
IV, the mutation segregates with disease within the family and there is a 
reduction in the steady-state level of the particular mitochondrial tRNA, 
which altogether suffice. 
According to the four canonical rules of DiMauro and Davidzon, (2005) 
a novel mtDNA mutation should be considered pathogenic if 1) the 
mutation is not present in normal individuals of the same ethnic group, 2) 
the mutation alters an evolutionarily conserved site, 3) the mutation causes 
respiratory chain enzyme deficiencies in affected tissues, and 4) there is a 
correlation between the degree of heteroplasmy and clinical phenotype. 
These criteria are more laborious to apply to the SAN-mutation. The first 
criterion is not fulfilled for dogs carrying the ∆T5304 mutation in the 
tRNA
Tyr gene, because maternally related but clinically unaffected dogs carry 
the same mutation. However, it is not clarified whether or not DiMauro 
and Davidzon (2005) included clinically unaffected maternal relatives as 
“normal individuals of the same ethnic group”. Most logically, in cases of 
mitochondrially inherited pathogenic mutations, there should be maternally 
related individuals carrying the same mutation. However, the SAN deletion 
is not present in any unrelated dog of the same breed. The second criterion, 
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deletion. For the third criterion, “affected tissues” are not defined further. 
For SAN, clinical signs of muscle dysfunction were not obvious but 
biochemical evidence of respiratory chain enzyme deficiencies was shown in 
muscle tissue, and the respiratory chain enzyme activities in malfunctioning 
nervous tissue were not analysed. For the fourth criterion, there was a 
correlation between the degree of heteroplasmy in blood and the clinical 
phenotype because all cases occurred in the part of the pedigree with the 
highest mutant load (Figure 1), but the mutant load in blood from affected 
dogs was not distinguishable from that in closely maternally related 
unaffected dogs. In humans, there are situations resembling SAN, e.g. 
documented pathogenic mutation in mtDNA with both affected and 
asymptomatic homoplasmic carriers of the same maternal lineage in the 
family (McFarland et al., 2004b).  
About  5% of dogs in the Swedish Golden Retriever population born 
during 2001–2005 was estimated to be carriers of this mutation (paper II). 
This figure presumed that the mean size of litters born to carrier bitches was 
the same as that of litters from unrelated bitches during this period. The 
mean litter size in the Golden Retriever breed in 2008 was 6.3 puppies per 
litter (http://www.rasdata.nu/). Looking at the sizes of the litters with 
affected dogs in the pedigree (Figure 1), the presumption seems reasonable, 
but no mathematical calculation was done. Moreover, all dogs descended 
from female Z (Figure 1) through maternal lineages that had been tested for 
the mutation in paper II were positive, suggesting that all her maternal 
descendants were carriers. In fact, two Golden Retriever dogs tested since 
then in this matrilineal family harboured 100% wild type mtDNA, and 
hence the proportion of carriers in the population was probably somewhat 
lower than assumed initially. 
A pathogenic single base-pair deletion in a mitochondrial tRNA gene 
seems rare and has previously been reported just a few times (Shoffner et al., 
1995; Raffelsberger et al., 2001), in humans. One of these reports concerns a 
deletion in the mitochondrial tRNA
Tyr gene (Raffelsberger et al.,  2001). 
Much more frequently reported mutations of mtDNA are pathogenic point 
mutations or large scale deletions (http://www.mitomap.org/). 
5.9  Molecular mechanisms - neurological signs 
The clinical features of dogs affected by SAN are surprisingly uniform in 
comparison with many human mitochondrial disorders. In addition, no 
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neuromuscular systems have been found.  
The correlation between genotype and clinical presentation of a 
mitochondrial disorder is not always easy to understand. For example, the 
same mutation can result in different human phenotypes, which is seen for 
example in the A3243G mutation in one of the mitochondrial tRNA genes 
for leucine. This affects different tissues with differing clinical signs in the 
three syndromes mitochondrial myopathy, encephalopathy, lactic acidosis, 
and stroke-like episodes (MELAS), chronic progressive external 
ophthalmoplegia (CPEO), and maternally inherited diabetes and deafness 
(MIDD) (Goto et al., 1990; Fang et al., 1993; van den Ouweland et al., 
1994). One mutation can also result in different disease courses and different 
ages at onset between affected humans, as for the T14709C-mutation in the 
mitochondrial tRNA gene for glutamic acid with congenital and late-onset 
forms of myopathy (Mancuso et al., 2005). A common phenotype can also 
develop from different mutations, e.g. the MELAS syndrome caused by 
mutations in either the protein encoding gene for MTND1 o r  t h a t  f o r  
MTND5, or the mitochondrial tRNA gene for leucine (Goto et al., 1990; 
Liolitsa et al., 2003; Kirby et al., 2004). A specific mutation can also give 
different human syndromes at different levels of heteroplasmy, e.g. the 
T8993G mutation in the MTATP6 gene that causes Leigh’s disease, with 
lactic acidosis, hypotonia and neurodegenerative disease at a high mutant 
load or ataxia and retinitis pigmentosa at a lower degree of heteroplasmy 
(Holt et al., 1990; Tatuch et al., 1992).  
The often confusing clinical signs and symptoms are, at least in part, 
correlated with different levels of heteroplasmy in different parts of the 
human body. This can be seen for example in different compartments of the 
same cell (Kärppä et al., 2005), or in different cells, for example different 
muscle cells (Sciacco et al., 1994; Moslemi et al., 1998). There can also be a 
discrepancy in mutant load between different tissues and organs in the body 
(Tanji et al., 2000). However, to fully explain the penetrance of mtDNA 
mutations in human medicine, further factors are needed. In many instances 
these factors are unknown, although for some mutations an important role 
for the nuclear genetic background has been shown (Dunbar et al., 1995; 
Cock  et al.,  1998; McFarland et al.,  2004b; Hudson et al.,  2005a). 
Interactions with other mitochondrial genes also seem to play a role for 
some phenotypes (Fischel-Ghodsian, 1998; Hudson et al., 2007). In addition, 
environmental factors may contribute to the disease presentation. For 
example, treatment with aminoglycoside antibiotics (Prezant et al.,  1993; 
Estivill et al., 1998) or smoking (Kirkman et al., 2009) have been shown to 
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humans.  
The mutant load in blood from SAN-dogs was high (>88%), and 
overlapped considerably with the mutant load in blood from dogs affected 
subclinically and unaffected 1
st to 4
th degree maternal relatives. The mutant 
load in tissues from affected dogs was even higher than in blood. No 
difference in the level of heteroplasmy has been found between neurological 
and non-neurological tissues, between different parts of nervous system or 
between single muscle fibres. So far, these figures have not been compared 
with the mutant load in tissues of any maternal relative. The penetrance of 
clinical disease may possibly be explained by this observation.  
The mutant load in blood was analysed by qOLA, as were tissues sampled 
post mortem from affected dogs. This quantification method was evaluated 
in paper II, where cloned plasmids containing wild type or mutant 
sequences were purified, diluted to the same concentration and mixed into 
dilution series. The method gave accurate estimates of values of 
heteroplasmy, even for extreme values (close to 0% and 100%). The 
resolution was not as good in the RFLP method applied for comparing 
heteroplasmy levels in single muscle fibres, and it is possible that variations of 
the degree of heteroplasmy within the range 0–2% wild type mtDNA 
between different fibres was present but remained undetected. 
The biochemical method used had not been evaluated on dogs, therefore 
the muscle samples from affected and age-matched control dogs were pair-
wise examined at the same occasion. One affected dog of the five included 
in the studies of mitochondria (dog 3, paper II) diverged from the other 
four. On histochemistry, no indication for a lowered COX activity was seen 
and by biochemistry no affection on the rate of ATP production or the 
activities of the respiratory chain enzymes could be found in comparison 
with the age-matched control dog of this affected dog. The mtDNA genetic 
content of these samples was double-checked afterwards (Table S1 in paper 
II). This excluded the possibility that the samples had been mixed up, and 
the outcome was instead considered to be a result of a mosaic pattern of 
heteroplasmy (Dufour et al., 2008). On the other hand, this dog was the 
only one that showed clear signs of mitochondrial pathology (paracrystalline 
inclusions) on the muscle biopsy section analysed by electron microscopy. 
The inference from this finding was that this dog also had muscle fibres that 
were affected by the mtDNA deletion.  
Histochemistry was also performed on muscle tissue from dogs 
undergoing post mortem examinations. No ragged red fibres were found, 
nor were any completely COX-negative fibres detected. The lack of control 
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indications for a lowered COX activity could be detected by increased 
bluish staining compared with controls.  
Assuming that the mutant load in blood shows some correlation with the 
mutant load in nervous tissue in both affected and related animals, the 
phenotypic expression of canine SAN requires a high mutant load of the 
pathogenic deletion and penetrates at a low frequency. Based on the studies 
performed, the factors that lead to penetrance are undetermined and 
involvement from the nuclear genetic background cannot be excluded. 
There are no indications for interacting mitochondrial genes, because the 
affected and related dogs were of the same mitochondrial haplotype.  
No conspicuous differences in environmental factors between affected 
dogs and their unaffected maternal relatives were suggested from the history. 
However, no systematic epidemiological study was conducted and the 
owners were not asked about, for example, the presence of smoking in the 
home.   
A few mutations suspected or proven to be pathogenic have been 
reported in humans in the mitochondrial tRNA
Tyr gene, albeit at other 
positions in the gene. One common neuromuscular symptom is chronic 
progressive external ophthalmoplegia (Pulkes et al., 2000; Raffelsberger et al., 
2001; Sahashi et al., 2001; Scaglia et al., 2003). Thus, a mutated tRNA
Tyr gene 
per se does not give a uniform phenotype in humans and dogs. However, 
one of the dogs, in addition to the gait abnormalities, showed strabismus on 
excitement, according to the owner. This may well be correlated with a 
mitochondrial myopathy of the extraocular muscles of the same kind as seen 
in chronic progressive external ophthalmoplegia. Chronic progressive 
external ophthalmoplegia is a common feature in many mitochondrial 
disorders of humans, both syndromic and non-syndromic, and thus is not 
unique for mitochondrial tRNA
Tyr mutations. 
Sensory ataxic neuropathy as the presenting feature of a mitochondrial 
disease in humans is often combined with dysarthria and ophthalmoplegia 
(SANDO) (Fadic et al., 1997; Van Goethem et al., 2003; Okun & Bhatti, 
2004;  Gago  et al.,  2006; Milone et al.,  2008). Sensory ataxic neuropathy 
syndromes have been seen with mutations in the genes for POLG and 
Twinkle (Van Goethem et al., 2003; Van Goethem et al., 2004; Hudson et al., 
2005b; Gago et al., 2006; Milone et al., 2008). Twinkle and POLG are both 
nuclear encoded enzymes, which are needed in the replication of mtDNA. 
Acquired spontaneous mutations of the mtDNA may develop secondary to 
any of these mutations. Most commonly, mitochondriopathies correlated 
with sensory ataxic neuropathy syndromes in humans have been associated 
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base-pair deletion (or other single base-pair mutation) in mtDNA has not 
been reported for any human patient. 
5.10 Neuropathological changes - neurological signs 
Some but not all of the histopathological lesions observed in the dogs 
studied can be correlated with neurological deficits. The axonopathy in the 
PNS and the NAD-type appearance in the CNS, affecting large myelinated 
Ia/b-afferents and proprioceptive pathways, are both mirrored in the gait 
disturbance (ataxia and weak knee extension), posture (hyperextended carpi) 
and decreased spinal reflexes.  
The involvement of descending motor pathways seen on histopathology 
was not reflected clinically by paresis, but a mild motor dysfunction in the 
gait abnormalities could well overlap with the more evident sensory signs. 
However, the degenerative changes in ventral horn cells were not indicated 
by any clinically detectable lower motor neuron dysfunction. The 
pathomorphological changes observed in the extrapyramidal basal nuclei 
were not correlated with any clinical or neurological signs. Extrapyramidal 
nuclear lesions in dogs do not have to be correlated with clinical signs at all 
(de Lahunta & Glass, 2009b). A few (n=3) of the affected dogs (n=27) 
displayed truncal swaying on neurological examination, a sign commonly 
associated with cerebellar lesions. One of the dogs with truncal swaying was 
necropsied, but displayed no histopathological changes in the cerebellum. 
One possible explanation could be that the truncal swaying seen in these 
SAN-dogs is unrelated to the cerebellum, but instead reflects dysfunctioning  
afferent neurons from the spinal musculature. Changes in the ponto- and 
spinocerebellum were seen post mortem in some dogs, but the dogs with 
pathomorphological changes in the cerebellum had not shown truncal 
swaying or any other classical cerebellar signs. This lack of correlation 
between lesions in the cerebellum and cerebellar signs is difficult to explain. 
Possibly, the slow progress of degenerative processes may play a role. 
Asymptomatic cerebellar degeneration considered to precede cerebellar signs 
has been documented in humans (Yokota et al., 2006). 
Some other clinical signs occurred rarely, and possibly but not 
unambiguously were signs of a malfunctioning nervous system (i.e. 
decreased menace response, urinary incontinence, inability to swim, cow-
hocks, nibbling of the skin, absent ticklishness or hypersensitivity when 
touched). These signs could also have been coincidental findings. However, 
if any or all of them represent dysfunction in the nervous system, they are all 
  51 unspecific regarding neuroanatomical diagnosis, and neuropathological 
changes corresponding to them may be of an unspecific nature and 
localization. In addition, many affected male dogs were reported to urinate 
in the same way as bitches. Given that this behaviour is also seen in normal 
male dogs at an unknown frequency, the clinical relevance of this sign is 
doubtful. 
Post mortem examination of a mother of two affected dogs revealed 
neurodegenerative changes in some brainstem nuclei and in peripheral 
nerves, although not exactly the same picture as in affected dogs. 
Neurologically, this mother of two SAN-dogs had moderately decreased 
patellar reflexes bilaterally and was considered a subclinical case of SAN.  
The polyradiculoneuropathy correlates well with her hyporeflexia. The 
family history and conclusions from other findings and non-findings 
suggested a mitochondrial disease, but other aetiologies for the neurological 
alterations were not completely ruled out. For example, the histological 
phenotype had similarities to the steroid neuropathy seen in canine cases of 
Cushing’s disease, but adrenal glands and liver were without 
histopathological changes.  
To summarize, affected dogs that were necropsied 1-2 years-old had 
distinct neurological signs but the neuropathological changes were mild. In 
affected dogs necropsied 4-9 years-old, neurological signs retained the same 
characteristics as in the younger dogs, but neuropathological changes were 
more widespread than the corresponding neurological signs indicated. The 
pathomorphological appearance at end stage of this disease is not known 
since necropsied dogs were all euthanized.  
5.11 Molecular mechanisms - neuropathological changes 
The mitochondrial tRNA
Tyr molecules in dogs with SAN had impaired 
stability, and affected dogs had a decreased rate of ATP production. Affected 
dogs also had histopathological changes compatible with a neuron-sparing 
spongiosis in the basal nuclei, NAD-like changes, and a central–peripheral 
axonopathy. The typical features of NAD have been associated with 
disrupted axonal transport, leading to accumulation of synaptic proteins and 
membranous deposits in the dystrophic axons (Sisó et al., 2001). A decreased 
rate of ATP production in affected cells in the nervous system of affected 
dogs is presumed. Given that axonal transport is dependent upon oxidative 
metabolism (Ochs & Ranish, 1970) and synapses normally are densely 
packed with mitochondria (Ly & Verstreken, 2006), the appearance of NAD 
is probably correlated with the malfunctioning mitochondria and ATP 
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similarly supposed to be correlated with energy deficiency in affected nerve 
fibres. 
Neuronal cell death was not the most prominent histopathological feature 
of SAN, but some neuronal populations, in for example the putamen (a 
basal nucleus) and the ventral horns, were subject to cell death. Whether or 
not this was secondary to the axonopathy or was a primary event was not 
elucidated. The energy deficit could lead to cell death through 
excitotoxicity (Nardin & Johns, 2001). In addition, disruption of electron 
transport and ATP-production may result in generation of radical oxygen 
species (ROS), which activate apoptotic cell death (Zhang et al., 1998).  
The progressive nature of SAN is reflected by a more widespread 
distribution and increased severity of pathomorphological changes in older 
dogs than in younger dogs and there are also indications of ongoing 
neurodegeneration, i.e. Wallerian-like degeneration, in affected cases. The 
distribution of degenerative features by age in different nerve cell 
populations is mainly thought to reflect their general susceptibility to the 
intracellular metabolic derangement. Known mechanisms that underlie a 
temporal progression of neuropathological alterations between cells in 
involved pathways are trans-synaptic neuronal degeneration and retrograde 
degeneration (Summers et al., 1995), which possibly account for some of the 
progression seen. However, because there are no direct anatomical 
connections between the proprioceptive pathways and the basal nuclei, this 
cannot be the only explanation. Other mechanisms that may lead to disease 
progression in mitochondrial disorders are induction of trans-neuronal 
degeneration (Dufour et al., 2008), the “vicious cycle” initiated by the 
oxidative stress attributable to mitochondrial dysfunction, which leads to 
even further deterioration of mitochondrial function, or an accumulation of 
the mutant load over time in nerve cells. 
5.12 Molecular mechanisms - neuropathological changes - 
neurological signs 
In canine SAN, one specific mitochondrial mutation gives rise to a uniform 
clinical and pathomorphological picture in affected dogs, compared with the 
confusing pattern seen in many mitochondrial disorders in humans (see e.g. 
section 5.9). The factors that determine the penetrance of clinical signs in 
SAN are however not understood so far, because many of the dogs carrying 
a high mutant load (at least in blood) apparently never display any overt 
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been normal on neurological examination.  
Perhaps even more puzzling is the selective vulnerability of tissues to this 
mutation. The mutant load was high in all examined tissues from affected 
dogs (close to 100%), thus differences in tissue heteroplasmy is not thought 
to be an explanatory factor for the clinical and pathological involvement of 
certain specific cell populations. It is more likely, that interplay between 
mutated mtDNA and some tissue-specific expression of nuclear genes in 
affected cell populations contributes to the vulnerability. In addition, ATP 
has other roles than energy storage, where a decreased production rate 
perhaps can contribute to selective tissue vulnerability. Indeed, ATP acts as a 
neurotransmitter at purinergic receptors (P2X receptors). Interestingly, 
subgroups of these receptors are known from sensory neurons in the 
nociceptive system (Burnstock, 2000). Another contributing factor may be 
the direct involvement of different respiratory chain enzymes in other 
cellular metabolic pathways, e.g. cytochrome c, albeit nuclear encoded, is 
also a mediator for apoptosis (Zhivotovsky et al., 1998). Hypotheses that 
have been proposed to explain selective tissue vulnerability in human 
mitochondrial disorders include the role of mitochondrial diversity between 
different cell types (Kunz, 2003), more roles for tRNA genes in addition to 
involvement in mtDNA translation (DiMauro & Schon, 2001), and different 
mechanisms of action of mutations in different tRNA genes (DiMauro & 
Davidzon,  2005). A hypothesis for the specific vulnerability of retinal 
ganglion cells to mitochondrial dysfunction in Leber’s hereditary optic 
neuropathy was presented recently by Yu-Wai-Man et al. ( 2009). These 
authors suggested that the abrupt mitochondrial concentration gradient 
normally seen at the transition from unmyelinated to myelinated segments of 
the optic nerve is maintained by active processes that involve the 
cytoskeletal architecture. They proposed that even subtle mitochondrial 
energy deficits result in impaired axonal transport, fragmentation of the 
mitochondrial network and eventually apoptotic cell death. However, this 
theory does not explain why these transition zones are not affected in other 
mitochondrial diseases with ubiquitous mitochondrial energy deficits. With 
respect to SAN in Golden Retriever dogs, optic nerves from three affected 
dogs (of three examined) were close to homoplasmic for the mutation and 
hence were considered likely to suffer from a decreased rate of ATP 
production, but no dog displayed visual deficits or had neuropathological 
changes detected in the visual pathways. 
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mitochondrially inherited disease 
Only one study of a spontaneous and maternally inherited condition in dogs 
with a causative mutation in the mtDNA has been reported previously (Li et 
al.,  2006). In that case, the mutation was in a protein encoding gene, 
whereas the SAN mutation is in a tRNA gene. In contrast to Golden 
Retriever dogs with SAN, the affected dogs reported by Li et al. (2006) were 
all dead when their disease was proposed to be a mitochondrial disorder, 
preventing all prospective investigations in the light of their disease being a 
mitochondrial disorder. Another spontaneous mitochondrial disease, 
pyruvate dehydrogenase phosphatase I deficiency in Clumber Spaniels and 
Sussex Spaniels, was also reported as a canine model for a mitochondrial 
disease with a proven genetic background (Cameron et al., 2007). In that 
case, the mutation was in the nuclear DNA and the inheritance pattern was 
not maternal. 
Documentation of this spontaneous mitochondrially transmitted disease 
in Golden Retriever dogs makes a contribution to mitochondrial medicine 
in general. There are some murine models that have been generated with 
mtDNA mutations (Larsson et al., 1998; Inoue et al., 2000; Sligh et al., 2000; 
Trifunovic et al., 2004), but owing to difficulties in introducing mtDNA 
into the mitochondria, there is a lack of good laboratory animal models 
(DiMauro & Davidzon, 2005; Taylor & Turnbull, 2005). No single model is 
considered really comparable to authentic mitochondrial diseases (Taylor & 
Turnbull, 2005; Kang & Hamasaki, 2006).  
So called cybrid cells have been produced by fusing human cell lines that 
are completely devoid of mtDNA with enucleated cells containing 
functional mitochondria (King & Attardi, 1989). By using enucleated cells 
from patients that harbour a spontaneously occurring mtDNA mutation, this 
method can be used in vitro to test for the biochemical and cellular 
consequences of specific mtDNA mutations and also their interplay with 
different nuclear genetic backgrounds (Dunbar et al.,  1995;  Cock  et al., 
1998; Taylor & Turnbull, 2005). No cybrid cell system has been developed 
yet to test canine mtDNA mutations, to the author’s knowledge. However, 
cybrid cells can not replace in vivo models in understanding the clinical 
expression of mtDNA diseases (DiMauro & Davidzon, 2005). 
Mitochondrially inherited SAN in Golden Retriever dogs is now well 
described regarding its phenotype, clinical course and genotype thanks to a 
successful cooperation between dog owners, dog breeders, veterinarians and 
geneticists. This disease may thereby serve as an excellent animal model of a 
naturally occurring mitochondrial disease. 
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  56 6  Conclusions 
Maternally inherited SAN is a novel neurological syndrome in the Golden 
Retriever breed, which is suitable to serve as a naturally occurring animal 
model for mitochondrial diseases. 
 
¾  Affected dogs present with ataxia, reduced postural reactions and reduced 
spinal reflexes. They develop degenerative changes, i.e. central–
peripheral axonopathy, neuroaxonal dystrophy-type changes and basal 
nuclei encephalopathy, that are distributed in a specific anatomical 
pattern throughout the CNS and PNS. 
 
¾  SAN has a chronic, slowly progressive clinical course with onset during 
puppyhood. The prognosis is guarded with respect to a full-length dog 
life, with about half of affected dogs being euthanized before 4 years of 
age, because of neurological impairment.  
 
¾  SAN is a maternally transmitted mitochondrial disorder caused by a 
deletion in the mitochondrial tRNA
Tyr gene. By not using carrier bitches 
for breeding, the disease incidence can be reduced. 
 
¾  The phenotypic expression of SAN is associated with a high mutant load, 
but the disease seems to penetrate only at a low frequency. Therefore, 
the nuclear genetic background and/or some environmental factor may 
also be involved in the disease presentation.   
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  58 7  Future perspectives 
Several questions have arisen during this study that may be elucidated in the 
future. For example, have there been dogs carrying this mutation even 
before “female Z”, and if so, do they have matrilineal descendants anywhere 
in the world today? Is it possible to detect the degenerative nervous system 
lesions by magnetic resonance imaging, and if so, at what age? What role 
does the nuclear genetic background play in the clinical penetrance of this 
disease? What role does the expression of nuclear genes in different 
populations of nerve cells play to give the specific tissue vulnerability? 
Certainly, another perspective for the future is to elucidate the possible role 
of the mtDNA and the mitochondria in other canine neurodegenerative 
diseases.  
A major challenge with mitochondrial disorders is to find an explanation 
for the puzzling phenotype/genotype relationship, both regarding the 
penetrance of clinical disease and regarding the selective tissue vulnerability 
in affected individuals, canine SAN being no exception. One way to 
approach this question for SAN is to continue with the analysis of tissues 
from affected dogs and unaffected carriers, as well as from pathologically 
affected and unaffected tissues. A comparison between the mutant load in 
different tissues from maternal relatives and the load in affected dogs is 
planned. Also, an investigation of the level of heteroplasmy with a high-
resolution method such as qOLA in single cells of the nervous system from 
affected and related dogs would be of interest. An immunohistochemical 
characterization of degenerating cells in the nervous system of affected dogs 
is also planned. Studies of markers for neurodegeneration will be of help in 
understanding the pathogenesis of SAN and possibly also of other 
mitochondrial disorders, as will an investigation of respiratory chain enzymes 
in tissues by immunohistochemistry. In addition, a systematic study to search 
for triggering environmental factors is waiting to be done.  
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